Identifier
Created
Classification
Origin
07PARIS444
2007-02-05 14:17:00
UNCLASSIFIED
Embassy Paris
Cable title:
EMBASSY RESPONSE TO FDA REQUEST FOR REVIEW OF
how-tonull Lucia A Keegan 02/05/2007 05:17:06 PM From DB/Inbox: Lucia A Keegan Cable Text: UNCLAS PARIS 00444 SIPDIS cxparis: ACTION: SCI INFO: POL AGR UNESCO AMBO SCIO LABO ENGO ECSO DCM AMB ECON ESCI DISSEMINATION: SCIX CHARGE: PROG APPROVED: ESTH:RDRY DRAFTED: ESTH:KKATZER,APPTOUL CLEARED: NONE VZCZCFRI532 RR RUEAUSA RUEHC DE RUEHFR #0444 0361417 ZNR UUUUU ZZH R 051417Z FEB 07 FM AMEMBASSY PARIS TO RUEAUSA/DEPT OF HHS WASHDC INFO RUEHC/SECSTATE WASHDC 4694
UNCLAS PARIS 000444
SIPDIS
ACTION FOR DEPARTMENT OF HEALTH AND HUMAN SERVICES, FOR
FOOD AND DRUG ADMINISTRATION, ATTN: LOUIS ANN BEAVER,
OFFICE OF INTERNATIONAL PROGRAMS;
INFO STATE OES/IHA
E.O. 12958: N/A
TAGS: TBIO FR
SUBJECT: EMBASSY RESPONSE TO FDA REQUEST FOR REVIEW OF
PROPOSED GRANT FDA ORPHAN PRODUCT DEVELOPMENT AWARD: GRANT
1 RO1 FD 003371-01, PHASE II STUDY ETHANOL GEL L0122 VS
SOLUTION IN CVM: (IND 70,379; 02/06/06)
REF: STATE 05829
UNCLAS PARIS 000444
SIPDIS
ACTION FOR DEPARTMENT OF HEALTH AND HUMAN SERVICES, FOR
FOOD AND DRUG ADMINISTRATION, ATTN: LOUIS ANN BEAVER,
OFFICE OF INTERNATIONAL PROGRAMS;
INFO STATE OES/IHA
E.O. 12958: N/A
TAGS: TBIO FR
SUBJECT: EMBASSY RESPONSE TO FDA REQUEST FOR REVIEW OF
PROPOSED GRANT FDA ORPHAN PRODUCT DEVELOPMENT AWARD: GRANT
1 RO1 FD 003371-01, PHASE II STUDY ETHANOL GEL L0122 VS
SOLUTION IN CVM: (IND 70,379; 02/06/06)
REF: STATE 05829
1. U.S. Consul at Embassy's subsidiary American Presence
Post in Toulouse, France met with ORFAGEN President Patrick
Dupuy on 1 February in response to request in referenced
telegram. Consul confirms that a spin-off of Pierre Fabre
Laboratories, ORFAGEN, specializes in developing
dermatological treatments for rare conditions. The company
works closely with laboratories in the U.S., especially at
U.S. research universities, as well as with Pierre Fabre
researchers to develop its specialty products, although it
retains "ownership" of products. ORFAGEN plans to establish
a U.S. subsidiary in Vermont or New Jersey, employing
approximately fifteen people. The staff at its Toulouse
office are primarily pharmacists, two of whom plan to travel
to Baltimore at the end of February in connection with the
subject project. Mr. Dupuy expressed considerable interest
in the FDA grant.
2. Embassy sees no objection from a foreign policy
perspective to the provision of this award to ORFAGEN.
Please visit Paris' Classified Website at:
http://www.state.sgov.gov/p/eur/paris/index.c fm
STAPLETON
SIPDIS
ACTION FOR DEPARTMENT OF HEALTH AND HUMAN SERVICES, FOR
FOOD AND DRUG ADMINISTRATION, ATTN: LOUIS ANN BEAVER,
OFFICE OF INTERNATIONAL PROGRAMS;
INFO STATE OES/IHA
E.O. 12958: N/A
TAGS: TBIO FR
SUBJECT: EMBASSY RESPONSE TO FDA REQUEST FOR REVIEW OF
PROPOSED GRANT FDA ORPHAN PRODUCT DEVELOPMENT AWARD: GRANT
1 RO1 FD 003371-01, PHASE II STUDY ETHANOL GEL L0122 VS
SOLUTION IN CVM: (IND 70,379; 02/06/06)
REF: STATE 05829
1. U.S. Consul at Embassy's subsidiary American Presence
Post in Toulouse, France met with ORFAGEN President Patrick
Dupuy on 1 February in response to request in referenced
telegram. Consul confirms that a spin-off of Pierre Fabre
Laboratories, ORFAGEN, specializes in developing
dermatological treatments for rare conditions. The company
works closely with laboratories in the U.S., especially at
U.S. research universities, as well as with Pierre Fabre
researchers to develop its specialty products, although it
retains "ownership" of products. ORFAGEN plans to establish
a U.S. subsidiary in Vermont or New Jersey, employing
approximately fifteen people. The staff at its Toulouse
office are primarily pharmacists, two of whom plan to travel
to Baltimore at the end of February in connection with the
subject project. Mr. Dupuy expressed considerable interest
in the FDA grant.
2. Embassy sees no objection from a foreign policy
perspective to the provision of this award to ORFAGEN.
Please visit Paris' Classified Website at:
http://www.state.sgov.gov/p/eur/paris/index.c fm
STAPLETON